海角破解版

EasySep? Human CD3 Positive Selection Kit II

Immunomagnetic positive selection of human CD3+ cells

EasySep? Human CD3 Positive Selection Kit II

Immunomagnetic positive selection of human CD3+ cells

Catalog #
(Select a product)
Immunomagnetic positive selection of human CD3+ cells
Request Pricing Request Pricing

Product Advantages


  • Fast and easy-to-use

  • Up to 99% purity

  • No columns required

What's Included

  • EasySep? Human CD3 Positive Selection Kit II (Catalog #17851)
    • EasySep? Human CD3 Positive Selection Cocktail II, 1 mL
    • EasySep? Dextran RapidSpheres? 50100, 1 mL
  • EasySep? Human CD3 Positive Selection Kit II (Catalog #100-0692)
    • EasySep? Human CD3 Positive Selection Cocktail II, 1 x 10 mL
    • EasySep? Dextran RapidSpheres? 50103, 2 x 1 mL
  • RoboSep? Human CD3 Positive Selection Kit II (Catalog #17851RF)
    • EasySep? Human CD3 Positive Selection Cocktail II, 1 mL
    • EasySep? Dextran RapidSpheres? 50100, 1 mL
    • RoboSep? Buffer (Catalog #20104)
    • RoboSep? Filter Tips (Catalog #20125)
Products for Your Protocol
To see all required products for your protocol, please consult the Protocols and Documentation.

Overview

Isolate highly purified human CD3+ cells from fresh or previously frozen human peripheral blood mononuclear cells (PBMCs) or washed leukapheresis samples by immunomagnetic positive selection, with the EasySep? Human CD3 Positive Selection Kit II. Widely used in published research for more than 20 years, EasySep? combines the specificity of monoclonal antibodies with the simplicity of a column-free magnetic system.

In this EasySep? positive selection procedure, desired cells are labeled with antibody complexes recognizing CD3 and magnetic particles. The cocktail in this kit also contains an antibody to human Fc receptor to prevent non-specific binding. Labeled cells are separated using an EasySep? magnet and by simply pouring or pipetting off the unwanted cells. The cells of interest remain in the tube. Following magnetic cell isolation in as little as 15 minutes, the desired CD3+ cells are ready for downstream applications such as flow cytometry, culture, or DNA/RNA extraction.

This product replaces the EasySep? Human CD3 Positive Selection Kit (Catalog #18051) for even faster cell isolations.

For large-scale isolation of human CD3+ cells from leukapheresis samples, see the large-format (1x10^10 cells) kit (Catalog #100-0692).

Learn more about how immunomagnetic EasySep? technology works or how to fully automate immunomagnetic cell isolation with RoboSep?. Explore additional products optimized for your workflow, including culture media, supplements, antibodies, and more.

Magnet Compatibility
? EasySep? Magnet (Catalog #18000)
? “The Big Easy” EasySep? Magnet (Catalog #18001)
? EasyPlate? EasySep? Magnet (Catalog #18102)
? EasyEights? EasySep? Magnet (Catalog #18103)
? Easy 50 EasySep? Magnet (Catalog #18002)
? RoboSep?-S (Catalog #21000)
? Easy 250 EasySep? Magnet (Catalog #100-0821)
Subtype
Cell Isolation Kits
Cell Type
T Cells
Species
Human
Sample Source
PBMC
Selection Method
Positive
Application
Cell Isolation
Brand
EasySep, RoboSep
Area of Interest
Chimerism, Immunology, Cell Therapy Development

Data Figures

Typical FACS Results with EasySep? Human CD3 Positive Selection Kit II

Figure 1: Typical FACS Results with EasySep? Human CD3 Positive Selection Kit II

Starting with a single cell suspension of human PBMCs, the CD3+ cell content of the isolated fraction is typically 99.2 ± 0.2% (mean ± SD), using the purple EasySep? Magnet.

FACS Data for Anti-Human CD8a Antibody, Clone RPA-T8, FITC-Conjugated

Figure 2: FACS Data for Anti-Human CD8a Antibody, Clone RPA-T8, FITC-Conjugated

(A) Flow cytometry analysis of human peripheral blood mononuclear cells (PBMCs) labeled with Anti-Human CD8a Antibody, Clone RPA-T8, FITC (Catalog # 60022FI; filled histogram) or a mouse IgG1, kappa FITC isotype control antibody (solid line histogram). (B) Flow cytometry analysis of human PBMCs processed with the EasySep? Human CD3 Positive Selection Kit (Catalog #17851) and labeled with Anti-Human CD8a Antibody, Clone RPA-T8, FITC. Histograms show labeling of PBMCs (Start) and isolated cells (Isolated). Labeling of start cells with a mouse IgG1, kappa FITC isotype control antibody is shown (solid line histogram).

FACS Data for Anti-Human CD4 Antibody, Clone OKT4, Alexa Fluor? 488-Conjugated

Figure 3: FACS Data for Anti-Human CD4 Antibody, Clone OKT4, Alexa Fluor? 488-Conjugated

(A) Flow cytometry analysis of human peripheral blood mononuclear cells (PBMCs) labeled with Anti-Human CD4 Antibody, Clone OKT4, Alexa Fluor? 488 (Catalog #60016AD) and Anti-Human CD45 Antibody, Clone HI30, APC (Catalog #60018AZ). (B) Flow cytometry analysis of human PBMCs isolated with the EasySep? Human CD3 Positive Selection Kit (Catalog #17851) and labeled with Anti-Human CD4 Antibody, Clone OKT4, Alexa Fluor? 488. Histograms show labeling of total PBMCs (Start) and isolated cells (Isolated). Labeling with Mouse IgG2b, kappa Isotype Control Antibody, Clone MPC-11, Alexa Fluor? 488 (Catalog #60072AD) is shown in the bottom panel (solid line histogram). (C) Flow cytometry analysis of human PBMCs isolated with the EasySep? Human CD4 Positive Selection Kit (Catalog #17852) and labeled with Anti-Human CD4 Antibody, Clone OKT4, Alexa Fluor? 488. Histograms show labeling of total PBMCs (Start) and isolated cells (Isolated). Labeling with Mouse IgG2b, kappa Isotype Control Antibody, Clone MPC-11, Alexa Fluor? 488 is shown in the bottom panel (solid line histogram).

Protocols and Documentation

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type
Product Name
Catalog #
Lot #
Language
Document Type
Product Name
Catalog #
17851
Lot #
All
Language
English
Document Type
Product Name
Catalog #
17851
Lot #
All
Language
English
Document Type
Product Name
Catalog #
17851RF
Lot #
All
Language
English
Document Type
Product Name
Catalog #
100-0692
Lot #
All
Language
English
Document Type
Product Name
Catalog #
17851
Lot #
All
Language
English
Document Type
Product Name
Catalog #
17851
Lot #
All
Language
English
Document Type
Product Name
Catalog #
17851RF
Lot #
All
Language
English
Document Type
Product Name
Catalog #
17851RF
Lot #
All
Language
English
Document Type
Product Name
Catalog #
17851RF
Lot #
All
Language
English
Document Type
Product Name
Catalog #
100-0692
Lot #
All
Language
English
Document Type
Product Name
Catalog #
100-0692
Lot #
All
Language
English

Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

Resources and Publications

Frequently Asked Questions

Can EasySep™ be used for either positive or negative selection?

Yes. The EasySep™ kits use either a negative selection approach by targeting and removing unwanted cells or a positive selection approach targeting desired cells. Depletion kits are also available for the removal of cells with a specific undesired marker (e.g. GlyA).

How does the separation work?

Magnetic particles are crosslinked to cells using Tetrameric Antibody Complexes (TAC). When placed in the EasySep™ Magnet, labeled cells migrate to the wall of the tube. The unlabeled cells are then poured off into a separate fraction.

Which columns do I use?

The EasySep™ procedure is column-free. That's right - no columns!

How can I analyze the purity of my enriched sample?

The Product Information Sheet provided with each EasySep™ kit contains detailed staining information.

Can EasySep™ separations be automated?

Yes. RoboSep™, the fully automated cell separator, automates all EasySep™ labeling and cell separation steps.

Can EasySep™ be used to isolate rare cells?

Yes. We recommend a cell concentration of 2x108 cells/mL and a minimum working volume of 100 µL. Samples containing 2x107 cells or fewer should be suspended in 100 µL of buffer.

Are the EasySep™ magnetic particles FACS-compatible?

Yes, the EasySep™ particles are flow cytometry-compatible, as they are very uniform in size and about 5000X smaller than other commercially available magnetic beads used with column-free systems.

Can the EasySep™ magnetic particles be removed after enrichment?

No, but due to the small size of these particles, they will not interfere with downstream applications.

Can I alter the separation time in the magnet?

Yes; however, this may impact the kit's performance. The provided EasySep™ protocols have already been optimized to balance purity, recovery and time spent on the isolation.

For positive selection, can I perform more than 3 separations to increase purity?

Yes, the purity of targeted cells will increase with additional rounds of separations; however, cell recovery will decrease.

How does the binding of the EasySep™ magnetic particle affect the cells? is the function of positively selected cells altered by the bound particles?

Hundreds of publications have used cells selected with EasySep™ positive selection kits for functional studies. Our in-house experiments also confirm that selected cells are not functionally altered by the EasySep™ magnetic particles.

If particle binding is a key concern, we offer two options for negative selection. The EasySep™ negative selection kits can isolate untouched cells with comparable purities, while RosetteSep™ can isolate untouched cells directly from whole blood without using particles or magnets.

Publications (31)

Heterogeneous Activated B Cell Compartments Arising Early and Transiently After SARS‐CoV‐2 Vaccination L. F. Blanco et al. European Journal of Immunology 2026 Mar

Abstract

In humans, the stages and dynamics of B cell development after antigen encounter remain unclear. Identifying early B cell differentiation stages could reveal biomarkers for humoral immunity and potential targets to prevent unwanted antibody responses. We characterized antigen‐specific B cell responses longitudinally after SARS‐CoV‐2 mRNA vaccination using multiparameter spectral flow cytometry. Spike‐specific IgG+ CD27+ CD71+ activated B cells (ActBCs), presumed to be germinal center‐derived and IgG+ DN2 extrafollicular B cells, dominated the early antigen‐specific B cell response, while memory B cells were the main population 6 months after vaccination. Within the IgG+ ActBC compartment, we delineated six novel clusters with specific contraction dynamics. Following the second vaccination, certain ActBC clusters displayed sustained expansion over time, being phenotypically similar to memory B cells, while others strongly expanded and subsequently contracted. Several of the rapidly contracting ActBC clusters expressed CD11c, a defining marker for atypical B cells, suggesting a possible extrafollicular origin of these clusters. The transient presence of heterogeneous ActBC clusters was also observed for total B cells when gated in an antigen‐independent manner. Characterization of novel ActBC clusters early after antigen encounter helps delineate and dissect the complexity of B cell differentiation, which is vital for understanding unwanted B cell responses. Characterization of the early antigen‐specific B cell response post‐SARS‐CoV‐2 vaccination reveals novel activated B cell clusters, showing different phenotypes and contraction dynamics. Some short‐lived activated B cells expressed both CD71 and the extrafollicular marker CD11c. These results advance our understanding of B‐cell differentiation regulation and biomarker potential.
Senescent human fibroblasts have increased FasL expression and impair the tumor immune response M. Cruz-Barrera et al. Frontiers in Immunology 2025 Oct

Abstract

Syngeneic mouse tumor models have shown that senescence influences the tumor immune response in multiple ways, including the induction of an immunosuppressive microenvironment or the promotion of immune cell recruitment. Yet, the impact of senescence on the tumor immune response in a humanized setting remains largely unexplored. MethodsTo address this question, we employed a combination cells co-culture models, tumor spheroids and mice bearing tumors immunogenic to human immune cells derived from the same donor. Results: We found that senescent fibroblasts exert a dual effect by enhancing the recruitment of immune cells into the tumor microenvironment while simultaneously promoting the apoptosis of T and NK cells. Mechanistically, we demonstrate that this apoptosis is primarily due to increased Fas ligand (FasL) expression on the surface of senescent fibroblasts. Increased FasL expression was observed on different human fibroblast cell lines in response to different senescence inducers with a particular robust effect in response to RAS-induced senescence. Deletion of FasL on fibroblasts was sufficient to prevent immune cell death and increase tumor cell killing in mice. Discussion: Our results identified the expression of FasL expression as a novel component of the senescent tumor microenvironment and highlight the importance of evaluating the impact of therapy-induced senescence in humanized models to understand and predict the outcome of cancer treatments.
Identification and characterization of a ubiquitin E3 RING ligase of the Chlamydia-like bacterium Simkania negevensis E-M. H?rner et al. PLOS Pathogens 2025 Nov

Abstract

In the arms race between a pathogen and the host, the defense mechanisms of the host cell, including the ubiquitin system, are often counteracted by bacteria. Simkania negevensis (Sne), an obligate intracellular Chlamydia-like bacterium connected with respiratory diseases, possesses numerous deubiquitinases, but not much is known about its other ubiquitin-modifying enzymes. Sne infects a wide range of hosts, developing inside a tubular vacuole in close contact with the host endoplasmic reticulum (ER) and mitochondria. Our study describes an uncharacterized Sne ubiquitin E3 RING-ligase (SNE_A12920 or SneRING), which primarily generates K63- and K11-linked ubiquitin chains and preferentially interacts with UbcH5b and UBE2T E2 enzymes. SneRING is expressed upon infection of various human cell lines, as well as amoebae. We show that a portion of the expressed SneRING co-localizes with mitochondria and ER and that the SneRING interactome includes mitochondrial and ER proteins involved in organelle morphology and stress response. Our work offers an initial characterization of a bacterial RING ligase potentially involved in the host cell remodeling to accommodate the unique intracellular lifestyle of Sne. Author summaryUbiquitination is a protein modification system that regulates protein degradation, localization, or interactions. As such, ubiquitination has many important functions in cell signalling, and its dysregulation can lead to cancer and neurodegenerative diseases. Bacteria that live and develop inside human or other eukaryotic cells, such as Chlamydia, often modulate the ubiquitination system to ensure their own survival. Simkania negevensis is a Chlamydia-like bacterium connected to respiratory diseases in humans. We have discovered a novel enzyme expressed by these bacteria that can ubiquitinate other proteins and thus potentially modify host cell processes that would otherwise hinder infection. In this work, we explore the function of this enzyme and determine its possible cellular localization, as well as some of the proteins it interacts with. Our study provides new insights into how bacterial pathogens adapt to and manipulate host cells using one of the major cell function regulatory systems.